Full metadata record
DC FieldValueLanguage
dc.contributor.authorHu, Guodong-
dc.contributor.authorWang, Xiu-
dc.contributor.authorHan, Yi-
dc.contributor.authorWang, Ping-
dc.date.accessioned2019-04-05T07:34:17Z-
dc.date.available2019-04-05T07:34:17Z-
dc.date.issued2018-11-20-
dc.identifier.issn1611-2156-
dc.identifier.urihttp://hdl.handle.net/2003/37982-
dc.identifier.urihttp://dx.doi.org/10.17877/DE290R-19966-
dc.description.abstractProtein arginine methyltransferase 5 (PRMT5) has emerged as a key regulator of tumorigenesis. However, how PRMT5 functions in bladder cancer, the most common malignancy of the urological system, is unknown. We described here that PRMT5 is highly expressed in bladder cancer cell lines and primary human bladder cancer tissues. PRMT5 enhances the proliferation and colony formation of bladder cancer cells. PRMT5 knockdown induces bladder cancer cell apoptosis. Mechanistically, PRMT5 enhances NF-kB activation by targeting crucial anti-apoptotic genes such as BCLXL and c-IAP1, thereby inhibiting tumor cell apoptosis and sustaining proliferation. Importantly, PRMT5 inhibitor opposed tumor growth and BCLXL and c-IAP1 transcription in the bladder cancer xenograft model. Collectively, the current suggests the crucial role of PRMT5 as a promising therapeutic target in bladder cancers.en
dc.language.isoen-
dc.relation.ispartofseriesEXCLI Journal;Vol. 17 2018-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subjectPRMT5en
dc.subjectBladder canceren
dc.subjectNF-kBen
dc.subjectApoptosisen
dc.subject.ddc610-
dc.titleProtein arginine methyltransferase 5 promotes bladder cancer growth through inhibiting NF-kB dependent apoptosisen
dc.typeText-
dc.type.publicationtypearticle-
dcterms.accessRightsopen access-
eldorado.dnb.zdberstkatid2132560-1-
eldorado.secondarypublicationtrue-
Appears in Collections:Original Articles

Files in This Item:
File Description SizeFormat 
Wang_20112018_proof.pdfDNB890.21 kBAdobe PDFView/Open


This item is protected by original copyright



This item is licensed under a Creative Commons License Creative Commons